Relay Therapeutics, Inc. (RLAY)

NASDAQ: RLAY · IEX Real-Time Price · USD
21.46
0.00 (0.00%)
Feb 1, 2023, 10:25 AM EST - Market open
Market Cap 2.59B
Revenue (ttm) 1.70M
Net Income (ttm) -290.46M
Shares Out 120.90M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 84,267
Open 21.39
Previous Close 21.46
Day's Range 21.14 - 21.78
52-Week Range 12.65 - 35.36
Beta 1.01
Analysts Buy
Price Target 37.94 (+76.79%)
Earnings Date Feb 22, 2023

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2020
Employees 320
Stock Exchange NASDAQ
Ticker Symbol RLAY
Full Company Profile

Financial Performance

In 2021, RLAY's revenue was $3.03 million, a decrease of -96.34% compared to the previous year's $82.65 million. Losses were -$363.87 million, 58.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for RLAY stock is "Buy." The 12-month stock price forecast is $37.94, which is an increase of 76.79% from the latest price.

Price Target
$37.94
(76.79% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?

Relay Therapeutics, Inc. (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p...

2 weeks ago - Zacks Investment Research

Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

1 month ago - GlobeNewsWire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the H.C. Wainwright 3rd Annual Precision Onc...

3 months ago - GlobeNewsWire

Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -7.04% and 31.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...

3 months ago - Zacks Investment Research

Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve

3 months ago - GlobeNewsWire

Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

3 months ago - GlobeNewsWire

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...

4 months ago - GlobeNewsWire

7 Unknown Biotech Stocks That Could Rocket in 2023

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

4 months ago - InvestorPlace

Relay Therapeutics (NASDAQ:RLAY) – Why Relay Therapeutics Shares Are Getting Hammered

Relay Therapeutics Inc (NASDAQ: RLAY) shares are trading lower by 11.33% to $25.54 Tuesday morning after the company priced a roughly 11.32 million share public offering of common stock at $26.50 per ...

5 months ago - Benzinga

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...

5 months ago - GlobeNewsWire

Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay's Investigational FGFR2 Inhibitor, RLY-4008

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company tran...

5 months ago - Business Wire

Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-naïve  FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose

5 months ago - GlobeNewsWire

Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress

Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T. Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T.

5 months ago - GlobeNewsWire

Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

6 months ago - GlobeNewsWire

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi) treatment-naïve FGFR2-fusion cholangiocarcinoma (...

7 months ago - GlobeNewsWire

Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event

CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

8 months ago - GlobeNewsWire

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference

CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference o...

9 months ago - GlobeNewsWire

Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform toxicities in the treatment of patients with FGFR2-...

1 year ago - GlobeNewsWire

Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

1 year ago - GlobeNewsWire

Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at...

1 year ago - GlobeNewsWire

Biotech: Interest ‘in vaccine stocks will probably wane,' strategist says

Michael Yee, Managing Director at Jefferies, discusses Adagio and its treatment for COVID-19 as well as the outlook for Moderna in 2022 on Yahoo Finance Live.

Other symbols: ADPTGSKKYMRMRNAVIR
1 year ago - Yahoo Finance

Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination

RLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast cancer models RLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast canc...

1 year ago - GlobeNewsWire

Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

1 year ago - GlobeNewsWire

Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

1 year ago - GlobeNewsWire

Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

EMERYVILLE, Calif.--(BUSINESS WIRE)--Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, a...

1 year ago - Business Wire